NFATc1-IN-1
NFATc1-IN-1 (compound A04) is a potent inhibitor of RANKL-induced osteoclast formation, with an IC50 of 1.57 μM. NFATc1-IN-1 shows anti-osteoclastogenic effects through reducing the RANKL-induced nuclear translocation of NFATc1. NFATc1-IN-1 can be used for osteoclastic diseases research[1].
Product Specifications
CAS Number
1912422-56-0
UNSPSC
12352005
Hazard Statement
H302
Target
Nuclear Factor of activated T Cells (NFAT)
Type
Reference compound
Related Pathways
Immunology/Inflammation
Applications
COVID-19-immunoregulation
Field of Research
Others
Assay Protocol
https://www.medchemexpress.com/nfatc1-in-1.html
Purity
99.97
Solubility
DMSO : 125 mg/mL (ultrasonic)
Smiles
OC1=C(C(NC2=C(F)C=C(I)C=C2)=O)C=C(F)C=C1
Molecular Formula
C13H8F2INO2
Molecular Weight
375.11
Precautions
H302
References & Citations
[1]Chen CL, et al. Design, synthesis and SARs of novel salicylanilides as potent inhibitors of RANKL-induced osteoclastogenesis and bone resorption. Eur J Med Chem. 2016 Jul 19;117:70-84.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
BNC400026-100 1x 100 µL
ACTH (Adrenocorticotrophic Hormone) (AH26), CF640R conjugate, 0.1mg/mL
Sign In for Pricing
View Details 
BNC040034-500 1x 500 µL
Cytokeratin 8/18 (C-51), CF405S conjugate, 0.1mg/mL
Sign In for Pricing
View Details 
BNC940745-100 1x 100 µL
CD45 / LCA (2B11 + PD7/26), CF594 conjugate, 0.1mg/mL
Sign In for Pricing
View Details 
BNC472055-500 1x 500 µL
Carcinoembryonic Antigen (CEA) / CD66 (C66/2055R), CF647 conjugate, 0.1mg/mL
Sign In for Pricing
View Details